Page 311 - Binder2

Chapter 6: Pharma’s Worst

Nightmare

Introduction – The Threat They Won’t Talk
About

In boardrooms across the pharmaceutical industry,
executives discuss emerging threats—biosimilars, price
controls, patent cliffs, AI-driven competition. But there’s
one topic that rarely makes the agenda, not because it isn’t
dangerous, but because it’s too dangerous:

Edible biologics.

Biologics that aren’t injected but swallowed.
Manufactured not in multi-billion-dollar facilities, but in
greenhouses.
Stable not in cold-chain refrigerators, but on shelves.
Delivered not through hospitals, but through capsules.

This chapter isn’t about what edible biologics could
become. It’s about what they already are—and why that
terrifies the pharmaceutical establishment.

Because if plant-grown drugs can deliver the same
therapeutic effect as their injectable counterparts, without
the cost, complexity, or infrastructure, the entire model
begins to collapse. The margin scaffolding crumbles. The
exclusivity fades. The gatekeeping ends.

It’s not science fiction. It’s chloroplast engineering. Freeze-
dried lettuce. Room-temperature enzymes. Shelf-stable
antibodies. And it’s happening—just not inside the
companies that profit from the old way.

309